These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28026816)

  • 21. Association of APC, GSTP1 and SOCS1 promoter methylation with the risk of hepatocellular carcinoma: a meta-analysis.
    Liu M; Cui LH; Li CC; Zhang L
    Eur J Cancer Prev; 2015 Nov; 24(6):470-83. PubMed ID: 25853848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
    Richiardi L; Fiano V; Vizzini L; De Marco L; Delsedime L; Akre O; Tos AG; Merletti F
    J Clin Oncol; 2009 Jul; 27(19):3161-8. PubMed ID: 19470943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.
    Van Neste L; Bigley J; Toll A; Otto G; Clark J; Delrée P; Van Criekinge W; Epstein JI
    BMC Urol; 2012 Jun; 12():16. PubMed ID: 22672250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.
    Martignano F; Gurioli G; Salvi S; Calistri D; Costantini M; Gunelli R; De Giorgi U; Foca F; Casadio V
    Dis Markers; 2016; 2016():4358292. PubMed ID: 27594734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of aberrant DNA methylation with clinicopathological features in breast cancer.
    Tserga A; Michalopoulos NV; Levidou G; Korkolopoulou P; Zografos G; Patsouris E; Saetta AA
    Oncol Rep; 2012 May; 27(5):1630-8. PubMed ID: 22159596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of RASSF1 promoter methylation in prostate cancer.
    Daniunaite K; Jarmalaite S; Kalinauskaite N; Petroska D; Laurinavicius A; Lazutka JR; Jankevicius F
    J Urol; 2014 Dec; 192(6):1849-55. PubMed ID: 24980613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer.
    Hashad DI; Hashad MM; Talaat IM; Ibrahim MA
    Genet Test Mol Biomarkers; 2011 Oct; 15(10):667-70. PubMed ID: 21631298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.
    Cairns P; Esteller M; Herman JG; Schoenberg M; Jeronimo C; Sanchez-Cespedes M; Chow NH; Grasso M; Wu L; Westra WB; Sidransky D
    Clin Cancer Res; 2001 Sep; 7(9):2727-30. PubMed ID: 11555585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation.
    Migheli F; Stoccoro A; Coppedè F; Wan Omar WA; Failli A; Consolini R; Seccia M; Spisni R; Miccoli P; Mathers JC; Migliore L
    PLoS One; 2013; 8(1):e52501. PubMed ID: 23326336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
    Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.
    Maldonado L; Brait M; Loyo M; Sullenberger L; Wang K; Peskoe SB; Rosenbaum E; Howard R; Toubaji A; Albadine R; Netto GJ; Hoque MO; Platz EA; Sidransky D
    J Urol; 2014 Nov; 192(5):1542-8. PubMed ID: 24769028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.
    Gonzalgo ML; Pavlovich CP; Lee SM; Nelson WG
    Clin Cancer Res; 2003 Jul; 9(7):2673-7. PubMed ID: 12855646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.
    Divyya S; Naushad SM; Murthy PV; Reddy ChR; Kutala VK
    Mol Biol Rep; 2013 Oct; 40(10):5541-50. PubMed ID: 23979608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
    Liu L; Kron KJ; Pethe VV; Demetrashvili N; Nesbitt ME; Trachtenberg J; Ozcelik H; Fleshner NE; Briollais L; van der Kwast TH; Bapat B
    Int J Cancer; 2011 Nov; 129(10):2454-62. PubMed ID: 21207416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer.
    Woodson K; O'Reilly KJ; Hanson JC; Nelson D; Walk EL; Tangrea JA
    J Urol; 2008 Feb; 179(2):508-11; discussion 511-2. PubMed ID: 18076912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.
    Delgado-Cruzata L; Hruby GW; Gonzalez K; McKiernan J; Benson MC; Santella RM; Shen J
    DNA Cell Biol; 2012 Feb; 31(2):187-92. PubMed ID: 21830905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.
    Partin AW; Van Neste L; Klein EA; Marks LS; Gee JR; Troyer DA; Rieger-Christ K; Jones JS; Magi-Galluzzi C; Mangold LA; Trock BJ; Lance RS; Bigley JW; Van Criekinge W; Epstein JI
    J Urol; 2014 Oct; 192(4):1081-7. PubMed ID: 24747657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.